Poly(ADP-ribose) Polymerase Inhibitors
Semantic Scholar uses AI to extract papers important to this topic.
PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed… Expand Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack of tumor… Expand Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by… Expand Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks. We recently… Expand Small-molecule inhibitors of PARP are thought to mediate their antitumor effects as catalytic inhibitors that block repair of DNA… Expand UNLABELLED
There is a need to improve treatments for metastatic breast cancer. Here, we show the activation of the… Expand Endothelial dysfunction is regarded as an important factor in the pathogenesis of vascular disease in obesity-related type 2… Expand Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no… Expand Poly(ADP-ribose) polymerase (PARP)-1 (EC 184.108.40.206) is a nuclear enzyme that promotes the base excision repair of DNA breaks… Expand We have previously demonstrated that deficiency of either the BRCA1 or BRCA2 breast cancer susceptibility proteins confers… Expand